Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a nationwide observational study

Awano, Nobuyasu; Jo, Taisuke; Izumo, Takehiro; Inomata, Minoru; Morita, Kojiro; Matsui, Hiroki; Fushimi, Kiyohide; Urushiyama, Hirokazu; Nagase, Takahide; Yasunaga, Hideo

doi:10.1186/s40560-022-00608-5

Journal of Intensive Care

Table 1 Baseline characteristics of patients before and after the stabilised IPTW using propensity scores

From: Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a nationwide observational study

Characteristics	All patients					Patients after IPTW estimation
Characteristics	mPSL alone group (n = 2602)	%	rTM group (n = 212)	%	SMD	mPSL alone group (n = 2611)	%	rTM group (n = 190)	%	SMD
Male sex	1962	75.4	159	75	− 0.9	1971	75.5	137	72.1	− 7.6
Age, years
15–70	640	24.6	64	30.2	12.6	655	25.1	54	28.4	8.2
71–80	1147	44.1	104	49.1	10	1159	44.4	91	47.9	6.7
≥ 80	805	30.9	43	20.3	− 24.6	787	30.1	43	22.6	− 17.2
Missing data	10	0.4	1	0.5	1.3	10	0.4	2	1.1	7.3
Treatment year
2014	546	21	38	17.9	− 7.7	541	20.7	36	18.9	− 4.6
2015	566	21.8	60	28.3	15.2	583	22.3	41	21.6	− 1.7
2016	531	20.4	43	20.3	− 0.3	532	20.4	41	21.6	3.7
2017	472	18.1	42	19.8	4.3	475	18.2	29	15.3	− 7.6
2018	487	18.7	29	13.7	− 13.7	482	18.5	42	22.1	9.7
BMI (kg/m²)
< 23	1282	49.3	105	49.5	0.5	1288	49.3	102	53.7	9.1
23–25	507	19.5	35	16.5	− 7.8	500	19.1	29	15.3	− 10.2
≥ 25	555	21.3	52	24.5	7.6	567	21.7	43	22.6	1.9
Missing data	258	9.9	20	9.4	− 1.6	257	9.8	16	8.4	− 5.2
Hugh–Jones dyspnoea score upon admission
1–2	205	7.9	15	7.1	− 3.1	202	7.7	13	6.8	− 3.2
3	168	6.5	8	3.8	− 12.2	163	6.2	11	5.8	− 2.7
4	329	12.6	23	10.8	− 5.6	324	12.4	18	9.5	− 9.7
5	1177	45.2	69	32.5	− 26.2	1154	44.2	85	44.7	0.7
Missing data	723	27.8	97	45.8	37.9	767	29.4	64	33.7	9
Japan Coma Scale score upon admission
0- or 1-digit (alert or dull)	2460	94.5	195	92	− 10.2	2463	94.3	180	94.7	2.7
2-digit (somnolence)	73	2.8	9	4.2	7.8	77	2.9	4	2.1	− 3.8
3-digit (coma)	69	2.7	8	3.8	6.4	72	2.8	5	2.6	0
Charlson Comorbidity Index
0	545	20.9	45	21.2	0.7	544	20.8	39	20.5	− 0.2
1	357	13.7	27	12.7	− 2.9	358	13.7	28	14.7	2.7
2	510	19.6	34	16	− 9.3	504	19.3	32	16.8	− 5.7
≥ 3	303	11.6	21	9.9	− 5.6	302	11.6	20	10.5	− 3.0
Missing data	887	34.1	85	40.1	12.5	904	34.6	70	36.8	4.7
Smoking index, pack-years
0	1113	42.8	79	37.3	− 11.3	1104	42.3	81	42.6	0.5
1–39	546	21	50	23.6	6.3	553	21.2	37	19.5	− 4.8
≥ 40	618	23.8	51	24.1	0.7	618	23.7	37	19.5	− 10.8
Missing data	325	12.5	32	15.1	7.6	337	12.9	36	18.9	16.7
ADL upon admission (Barthel Index)
100	519	19.9	53	25	12.1	526	20.1	33	17.4	− 6.6
≤ 95	1612	62	118	55.7	− 12.8	1607	61.5	120	63.2	3.7
Missing data	471	18.1	41	19.3	3.2	479	18.3	36	18.9	2.0
History of previous hospitalisation
0	1457	56	110	51.9	− 8.2	1455	55.7	108	56.8	2.4
1–2	792	30.4	78	36.8	13.5	807	30.9	57	30.0	− 1.9
≥ 3	353	13.6	24	11.3	− 6.8	350	13.4	25	13.2	− 0.9
Academic hospital	2169	83.4	179	84.4	2.9	2179	83.5	164	86.3	7.6
ICU admission	665	25.6	68	32.1	14.4	683	26.2	55	28.9	6.3

Data were presented as n (%)
BMI body mass index, ADL activities of daily living, ICU intensive care unit, IPTW inverse probability of treatment weighting, mPSL methylprednisolone, rTM recombinant human soluble thrombomodulin, SMD standardised mean difference

Back to article page

ISSN: 2052-0492

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com